Table 1.
Novel drugs in glycosylation-targeted immunotherapy.
| Reference | Drug Name | Drug Type | Target | Study Phase |
|---|---|---|---|---|
| [44] | STM408 | Monoclonal antibody | N58-glycosylated PD-1 | Preclinical study |
| [108] | MW11-h317 | Monoclonal antibody | N58-glycosylated PD-1 | Preclinical study |
| [109] | mAb059c | Monoclonal antibody | N58-glycosylated PD-1 | Preclinical study |
| [50] | STM108 | Monoclonal antibody | N-glycosylated PD-L1 | Preclinical study |
| [111] | BMS1166 | Small molecule | N-glycosylated PD-L1 | Preclinical study |
| [43,44,66] | 2F-Fuc | Glucose analog | FUT8 | Preclinical study |
| [67,112,113,114] | NGI-1 | Small molecule | STT3A/B | Preclinical study |
| [98,115,116] | 2-DG | Glucose analog | Hexokinase | Preclinical study |
| [119] | SEA-TGT | Monoclonal antibody | TIGIT | Clinical trial |